SAFETY ALERT: FDA Warns of Arrhythmias With Zofran

The FDA has notified healthcare professionals of an ongoing safety review and labeling changes for Zofran (ondansetron; GlaxoSmithKline) because of an increased risk of developing QT prolongation, which can lead to an abnormal and potentially fatal heart rhythm (including torsades de pointes).

Anzemet labeling updated to include warning of arrhythmia

The FDA has notified healthcare professionals that a Contraindication is being added to the labeling for Anzemet injection (dolasetron mesylate, from sanofi-aventis) advising that it no longer be used to prevent nausea and vomiting associated with cancer chemotherapy (CINV) in pediatric and adult patients.